The role of hormones in the treatment of spider telangiectasia of the lower extremities: Effects on efficacy and posttreatment complications

Cosmetic Dermatology

Volumn 16, Issue 2, 2003, Pages 44-49

  Sadick, Neil S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; TETRADECYL SULFATE SODIUM;

ADULT; ARTICLE; CAPILLARY RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ECCHYMOSIS; FEMALE; HUMAN; LASER; LEG; MAJOR CLINICAL STUDY; SCLEROTHERAPY; SIDE EFFECT; TELANGIECTASIA;

EID: 0038270165     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sadick NS Predisposing factors of varicose and telangiectatic leg veins. J Dermatol Surg Oncol. 1992;18:883-886.
2. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992;6:886-892.
3. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442-446.
4. Sadick NS, Urmacher C. Estrogen and progesterone receptors. Dermatol Surg. 1999;25:539-543.
5. Sadick NS, Niedt GW. A study of estrogen and progesterone receptors in spider telangiectasias of the lower extremities. J Dermatol Surg Oncol. 1990;16:620-623.
6. Perrot-Applanat M, Cohen-Solal K, Milgrom E, et al. Progesterone receptor expression in human saphenous veins. Circulation. 1995;92:2975-2983.
7. Mashiah A, Berman U, Thole HH, et al. Estrogen and progesterone receptors in normal and varicose saphenous veins. Cardiovasc Surg. 1999;7:327-331.
8. Folkman J. Clinical applications of research on angiogenesis. Semin Med Beth Isr Hosp. 1995;333:1757-1763.
9. Arbiser JL. Angiogenesis and the skin: a primer. J Am Acad Dermatol. 1996;34:486-497.
10. Ness R, Harris T, Cobb J, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med. 1993; 328:1528-1533.
11. Vin F, Allaert FA, Levardon M. Influence of estrogens and progesterone on the venous system of the lower limbs in women. J Dermatol Surg Oncol. 1992;18:888-892.
12. Paller AS. Responses to anti-angiogenic therapies. J Invest Dermatol Symp Proc. 2000;5:83-86.
13. Kanda N, Watanabe S. 17β-Estradiol enhances vascular endothelial growth factor production and dihydrotestosterone antagonizes the enhancement via the regulation of andenylate cyclase in differentiated THP-1 cells. J Invest Dermatol. 2002;118:519-529.
14. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature. 1982;297:307-312.
15. Davis LT, Duffy DM. Determination of incidence and risk factors for post-sclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol. 1990;16:327-330.